10.28.2024 - POLA

Check out this week's QuadCast as we discuss if PCV is better than TMZ for oligodendroglioma, discuss results of the hypo-FLAME trial for prostate cancer, highlight adjuvant RT for high risk bladder cancer in the BART trial, and more.

Om Podcasten

With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed four mornings each week so you can quickly down and digest the day's most pertinent cancer news.